Telix Completes US$600M Bond Issue at 1.5% and Retires 98% of Existing Debt
Telix completes US$600 million convertible bond issue with SGX listing
Telix Pharmaceuticals has successfully settled its US$600 million 1.50% Convertible Notes due 2031, with the bonds expected to list on the Singapore Exchange Securities Trading Limited (SGX-ST) on April 23, 2026. The notes were issued by Telix Pharmaceuticals (Investments) Inc. and are guaranteed by Telix Pharmaceuticals Limited and Telix Pharmaceuticals (US) Inc.
The settlement completes the capital structure optimisation announced in mid-April. The 1.50% coupon rate represents favourable terms for the company, reflecting strong institutional demand for Telix’s convertible debt.
J.P. Morgan Securities plc acted as Sole Bookrunner on the offering.
When big ASX news breaks, our subscribers know first
What are convertible bonds and why do companies use them?
Convertible bonds are debt instruments that give investors the option to convert their holdings into equity at a predetermined price if the company’s share price rises. They sit between traditional bonds and shares, offering bondholders fixed interest payments whilst retaining upside participation if the equity story performs.
Companies favour convertibles because they typically carry lower interest rates than traditional corporate bonds. The conversion feature compensates investors for accepting a smaller coupon. This structure also delays potential equity dilution, as shares are only issued if bondholders elect to convert rather than being issued upfront.
For investors, convertibles provide downside protection through the bond’s fixed income and principal repayment, whilst preserving upside exposure if the share price appreciates beyond the conversion price. The 1.50% coupon on Telix’s new bonds is notably low for a seven-year instrument, signalling that institutional investors placed significant value on the conversion optionality. They accepted minimal yield because they are confident in Telix’s equity trajectory.
Repurchase of existing bonds nears completion
Telix has repurchased approximately A$637 million of its existing A$650 million 2.375% Convertible Bonds due 2029, representing approximately 98% of the outstanding principal. The concurrent repurchase ran alongside the new bond issue, allowing Telix to refinance its convertible debt on improved terms.
With less than 15% of the original bonds remaining outstanding, Telix intends to exercise its right to repurchase and cancel all remaining bonds at principal amount plus accrued interest in accordance with the bond terms.
| Feature | Existing Bonds (Retired) | New Bonds |
|---|---|---|
| Principal | A$650 million | US$600 million |
| Coupon | 2.375% | 1.50% |
| Maturity | 2029 | 2031 |
| Listing | ASX | SGX-ST |
The near-complete participation rate in the repurchase demonstrates bondholder alignment with the refinancing strategy. Telix has effectively reduced its annual interest expense whilst extending its debt maturity by two years, improving cash flow flexibility and lengthening its capital runway.
Transaction advisors
J.P. Morgan Securities plc acted as Sole Bookrunner on the new bond offering and Sole Bookrunner and Sole Dealer Manager on the repurchase.
The next major ASX story will hit our subscribers first
Strategic implications for Telix’s capital position
The successful completion of this refinancing represents balance sheet optimisation rather than new strategic direction. Telix announced the transaction on April 14 and April 15, 2026, and has now executed it on favourable terms within the stated timeframe.
The company maintains a multi-jurisdictional capital markets presence. Its shares trade on the ASX and NASDAQ, whilst its convertible bonds now list on SGX-ST. This geographic distribution reflects Telix’s global institutional investor base and operational footprint, which spans Melbourne (headquarters), the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan.
The refinancing supports Telix’s ongoing commercialisation and development activities in radiopharmaceuticals, a specialised field focused on oncology and rare diseases.
- Lower coupon reduces annual interest expense — the 0.875 percentage point reduction from 2.375% to 1.50% improves cash flow available for operations and development.
- Extended maturity to 2031 provides longer runway — pushing out the maturity date by two years gives Telix additional time to advance its pipeline and commercialisation efforts without near-term refinancing pressure.
- SGX listing broadens investor access — listing on Singapore’s exchange alongside ASX and NASDAQ expands the bondholder base to Asian institutional investors.
- Near-complete tender (98%) shows bondholder alignment — the overwhelming participation rate in the repurchase confirms existing bondholders supported the refinancing strategy.
Telix continues to advance its radiopharmaceutical pipeline whilst maintaining financial flexibility through its optimised capital structure.
Don’t Miss the Next Biotech Breakthrough
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving biotech and pharma announcements delivered straight to your inbox the moment they break.